On the Scientific Misconduct Blog, Dr Aubrey Blumsohn
posted about the role of a Swedish disease-oriented patient advocacy group in the "Gillberg affair." The group, which apparently tried to discredit a whistle-blower in the case, turns out to be funded by the pharmaceutical industry. It looks like stealth advocacy is an international issue.
No comments:
Post a Comment